Published in Science on November 07, 1986
Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 4.45
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A (1996) 3.29
Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. Proc Natl Acad Sci U S A (1988) 2.30
Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28
Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci U S A (1987) 2.25
Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol (1998) 1.83
An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol (1994) 1.68
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol (1992) 1.55
Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms. J Virol (1998) 1.39
Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J Virol (1993) 1.36
Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol (1992) 1.33
Lymphocyte deficiencies increase susceptibility to friend virus-induced erythroleukemia in Fv-2 genetically resistant mice. J Virol (1999) 1.32
An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1990) 1.28
The amino-terminal half of rotavirus SA114fM VP4 protein contains a hemagglutination domain and primes for neutralizing antibodies to the virus. J Virol (1991) 1.25
FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens. J Exp Med (1989) 1.25
Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. J Clin Invest (1989) 1.25
Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB). J Virol (1988) 1.21
Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus. J Virol (1999) 1.18
Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein. J Virol (1992) 1.14
Genetic control of T cell responsiveness to the Friend murine leukemia virus envelope antigen. Identification of class II loci of the H-2 as immune response genes. J Exp Med (1988) 1.11
Role of natural killer cells in resistance against friend retrovirus-induced leukemia. J Virol (2001) 1.08
Protective cellular retroviral immunity requires both CD4+ and CD8+ immune T cells. J Virol (1991) 1.07
B lymphocyte activation by coinfection prevents immune control of friend virus infection. J Immunol (2008) 1.06
Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med (1992) 1.05
An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J Exp Med (1993) 1.04
Differing T-cell requirements for recombinant retrovirus vaccines. J Virol (1996) 1.02
Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol (1993) 1.01
Protection against establishment of retroviral persistence by vaccination with a live attenuated virus. J Virol (1999) 1.00
Inverse relationship of CD8+CD11+ suppressor T cells with human immunodeficiency virus (HIV)-specific cellular cytotoxicity and natural killer cell activity in HIV infection. Immunology (1991) 0.99
Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci U S A (1987) 0.99
Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci U S A (1988) 0.99
A single retroviral gag precursor signal peptide recognized by FBL-3 tumor-specific cytotoxic T lymphocytes. J Virol (1995) 0.97
Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J Virol (1996) 0.97
Vaccination with a live retrovirus: the nature of the protective immune response. Proc Natl Acad Sci U S A (1990) 0.95
Novel role of CD8(+) T cells and major histocompatibility complex class I genes in the generation of protective CD4(+) Th1 responses during retrovirus infection in mice. J Virol (2002) 0.93
Vaccinia virus vectors: new strategies for producing recombinant vaccines. Clin Microbiol Rev (1990) 0.92
Recombinant feline herpesviruses expressing feline leukemia virus envelope and gag proteins. J Virol (1990) 0.92
Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97. J Virol (1988) 0.91
Distinct roles of CD4+ T cell subpopulations in retroviral immunity: lessons from the Friend virus mouse model. Retrovirology (2011) 0.89
No evidence for xenotropic murine leukemia-related virus infection in Sweden using internally controlled multiepitope suspension array serology. Clin Vaccine Immunol (2012) 0.88
Humoral immunity in the Friend retrovirus infection model. Immunol Res (2013) 0.87
Contrasting effects from a single major histocompatibility complex class II molecule (H-2E) in recovery from Friend virus leukemia. J Virol (1994) 0.87
Approach to a retrovirus vaccine: immunization of mice against Friend virus disease with a replication-defective Friend murine leukemia virus. Proc Natl Acad Sci U S A (1992) 0.85
Requirement for CD4(+) T cells in the Friend murine retrovirus neutralizing antibody response: evidence for functional T cells in genetic low-recovery mice. J Virol (1998) 0.84
Interference established in mice by infection with Friend murine leukemia virus. J Virol (1992) 0.83
Fv1 restriction and retrovirus vaccine immunity in Apobec3-deficient 129P2 mice. PLoS One (2013) 0.79
Current approaches to vaccine preparation. Can Vet J (1990) 0.79
Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals. J Virol (1996) 0.78
Increased hematopoiesis in mice soon after infection by Friend murine leukemia virus. J Virol (1993) 0.77
Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery. Retrovirology (2017) 0.76
Analysis of two monoclonal antibodies reactive with envelope proteins of murine retroviruses: one pan specific antibody and one specific for Moloney leukemia virus. J Virol Methods (2014) 0.75
Immunology of HIV infection and AIDS: memorandum from a WHO/IUIS meeting. Bull World Health Organ (1987) 0.75
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A (1986) 32.58
Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol (1985) 13.99
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol (1988) 12.52
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 10.98
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 9.09
Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature (1986) 8.36
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A (1982) 7.81
Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76
Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol Cell Biol (1987) 6.13
Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07
In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J Virol (1985) 5.77
Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1985) 5.42
Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA. Proc Natl Acad Sci U S A (1982) 5.25
Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature (1983) 5.25
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. Proc Natl Acad Sci U S A (1989) 5.23
Methylated nucleotides block 5'-terminus of vaccinia virus messenger RNA. Proc Natl Acad Sci U S A (1975) 5.16
Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev (1994) 4.94
Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol (1988) 4.92
An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1988) 4.72
Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A (1983) 4.69
Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A (1992) 4.58
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 4.51
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1990) 4.46
Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 4.45
Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene. Cell (1981) 4.42
Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks. J Cell Biol (1993) 4.34
Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro. Proc Natl Acad Sci U S A (1993) 4.28
Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci U S A (1989) 4.26
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology (1983) 4.16
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14
Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous frameshift mutations. J Virol (1983) 3.95
Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene (1983) 3.94
Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology (1995) 3.87
Identification of the fusion peptide of primate immunodeficiency viruses. Science (1989) 3.83
Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J Virol (1991) 3.79
Rifampicin: a specific inhibitor of vaccinia virus assembly. Nature (1969) 3.74
Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques (1997) 3.74
Structure of vaccinia virus early promoters. J Mol Biol (1989) 3.73
Methylation of newly synthesized viral messenger RNA by an enzyme in vaccinia virus. Proc Natl Acad Sci U S A (1974) 3.68
Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem (1975) 3.66
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature (1985) 3.62
Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol (1991) 3.62
Eukaryotic transient expression system dependent on transcription factors and regulatory DNA sequences of vaccinia virus. Proc Natl Acad Sci U S A (1985) 3.61
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
Alternative equilibria in shallow lakes. Trends Ecol Evol (1993) 3.55
Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science (1985) 3.54
Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. J Virol (1992) 3.53
Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci U S A (1986) 3.53
Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. Virology (1987) 3.53
Formation of a vaccinia virus structural polypeptide from a higher molecular weight precursor: inhibition by rifampicin. Proc Natl Acad Sci U S A (1970) 3.50
Methylated nucleotides block 5' terminus of HeLa cell messenger RNA. Cell (1975) 3.46
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
Structure of vaccinia virus late promoters. J Mol Biol (1989) 3.42
Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature (1985) 3.38
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol (1994) 3.32
Inhibition of HeLa cell protein synthesis by the vaccinia virion. J Virol (1968) 3.28
Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol (1991) 3.28
Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science (1990) 3.26
Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J Virol (1992) 3.24
Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature (1984) 3.21
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature (1986) 3.19
Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane. J Virol (1990) 3.18
Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology (1997) 3.17
HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science (1988) 3.12
Cell-free translation of early and late mRNAs selected by hybridization to cloned DNA fragments derived from the left 14 million to 72 million daltons of the vaccinia virus genome. Virology (1981) 3.10
Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J Virol (1990) 3.07
Homology between DNA polymerases of poxviruses, herpesviruses, and adenoviruses: nucleotide sequence of the vaccinia virus DNA polymerase gene. Proc Natl Acad Sci U S A (1986) 3.07
Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature (1984) 3.03
Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med (1987) 3.02
Complete nucleotide sequences of two adjacent early vaccinia virus genes located within the inverted terminal repetition. J Virol (1982) 3.01
Interruption by Rifampin of an early stage in vaccinia virus morphogenesis: accumulation of membranes which are precursors of virus envelopes. J Virol (1970) 3.00
Surface expression of viral glycoproteins is polarized in epithelial cells infected with recombinant vaccinia viral vectors. EMBO J (1986) 3.00
A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J Virol (1990) 3.00